knowledge -WSS

knowledge

author：knowledge 2025-09-07 11:16:37 - browse：64647

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： What causes rare myocarditis in young men after Covid vaccines?

WSS

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Using force crossed my mind when examining a defiant young patient

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Will the FTC rein in IQVIA's health data empire?

5 ways to address the shortage of health care workers

Dems pitch expanding Medicare power to negotiate drug prices

focus

knowledge

explore

Medicare details structure of new drug price negotiation program

Virtual repurposing can help discover new uses for existing drugs

Hollywood unions extend contract negotiations for actors

Democrats decry new health bill for going easy on private equity

How to save PrEP access — and even expand it

Elisabeth Bik tackles the widespread issue of research misconduct

After affirmative action ruling, medical educators look to 'holistic review'

Democrats decry new health bill for going easy on private equity

In age of alternative facts, a scholarly course on calling out crap

The battle over 'scope creep' and who gets to be called 'doctor'

focus

STAT Madness 2024: Meet the contenders

How doctors’ personal politics affect patients

Readout Newsletter: Beam, Prozac, "TechBio" and more

5 ways to address the shortage of health care workers

Democrats decry new health bill for going easy on private equity

Using force crossed my mind when examining a defiant young patient

hotspot

hotspot

hotspot

hotspot